Observational studyEuropean journal of nuclear medicine and molecular imaging2024

The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [

Marco Maccauro et al.PubMed ↗Publisher ↗

No numbers read from the abstract.